HOME - The Journal of Precision Medicine

LATEST NEWS

Blueprint Medicines Reports Second Quarter 2022 Results

adminpmls20162022-08-10T21:02:03-05:00August 10th, 2022|

GenomOncology and Congenica announce collaborative development of novel Precision Oncology Solution

adminpmls20162022-08-10T20:54:23-05:00August 10th, 2022|

Metabolon Announces Joint Development Agreement with Mayo Clinic to Create New Diagnostic Tests

adminpmls20162022-08-10T20:50:25-05:00August 10th, 2022|

Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma

adminpmls20162022-08-10T20:46:27-05:00August 10th, 2022|

23andMe Pins Future on ‘Genomic Health Service,’ Therapeutic Development

adminpmls20162022-08-10T20:42:15-05:00August 10th, 2022|

Myocardial Infarction Features Found With Multiomic Molecular Map

adminpmls20162022-08-10T20:39:10-05:00August 10th, 2022|

Beyond 1M Genomes Project Releases Recommendations to Guide European Genomic Data Initiative

adminpmls20162022-08-10T20:34:45-05:00August 10th, 2022|

Oncology Business Pushes Invitae’s Q2 Revenues up 18 Percent

adminpmls20162022-08-10T20:31:51-05:00August 10th, 2022|

10x Genomics Lowers Full-Year 2022 Revenue Guidance by Approximately $100M

adminpmls20162022-08-10T20:27:43-05:00August 10th, 2022|

Blueprint Medicines Reports Second Quarter 2022 Results - thejournalofprecisionmedicine.com/blueprint-medi…
24 hours ago
GenomOncology and Congenica announce collaborative development of novel Precision Oncology Solution - thejournalofprecisionmedicine.com/genomoncology-…
24 hours ago
Metabolon Announces Joint Development Agreement with Mayo Clinic to Create New Diagnostic Tests - thejournalofprecisionmedicine.com/metabolon-anno…
1 day ago

LATEST ISSUE

The Journal of Precision Medicine - June 2022

The Center for Applied Genomics at The Children’s Hospital of Philadelphia: Perspectives on a Decade with the Electronic Medical Records and Genomics (eMERGE) Consortium

Clinical trials for the management of malignant lymphoma and leukemia

Drugging the Genome with a Novel and Scalable Therapeutic Modality to Address Diseases at the Base Level

The Biomarker to Companion Diagnostic Continuum

Advancing on a path to precision health by revealing the hidden signals in our healthcare data

A Humanistic Goal: Limiting Overtreatment Through Comprehensive Medication Management

A Clinical AI Application to Enable Accurate and Efficient Detection of Breast Cancer Metastases in Lymph Nodes

Proteomics at the heart of multiomic strategies to enable precision medicine

AWS Interoperability and Precision Medicine

Scalable multiplex CRISPR knockouts and a new knock-in research method to support personalized medicine discoveries

The SepSIGN Trial for Early Detection of Sepsis

ARCHIVE ISSUES

March 2022

Articles include:
Applications of Spatial‑Omics in Clinical Translational Cancer Research, Illumina‑SomaLogic Deal to bring together genomics and proteomics technology platforms, How I Learned the Hard Way to Ask Questions About Medications.

Read More

September 2021

Articles include:
The Integration of Personalized Medicine into Healthcare: Advancing the Promise to More Patients, The value of adding RNA sequencing to precision biomarker strategy, As Targeted Therapies Expand Beyond Cancer, Companion Diagnostics Must Improve.

Read More

June 2021

Articles include:
myRabble: A novel patient platform to improve access to personalized medicine, Clinical data and precision medicine: The urgent need for in‑house NGS capabilities at community hospitals.

Read More

March 2021

Articles include:
Integrating biomarker and translational research in a drug development pipeline, Early Detection of Cancer: Transitioning from Emerging to Established Companies and Technologies.

Read More

LATEST NEWS

Blueprint Medicines Reports Second Quarter 2022 Results

GenomOncology and Congenica announce collaborative development of novel Precision Oncology Solution

Metabolon Announces Joint Development Agreement with Mayo Clinic to Create New Diagnostic Tests

Bristol Myers Squibb and 2seventy bio Announce Topline Results from KarMMa-3 Trial Showing Abecma (idecabtagene vicleucel) Significantly Improves Progression-Free Survival Versus Standard Regimens in Relapsed and Refractory Multiple Myeloma

23andMe Pins Future on ‘Genomic Health Service,’ Therapeutic Development

Myocardial Infarction Features Found With Multiomic Molecular Map

Beyond 1M Genomes Project Releases Recommendations to Guide European Genomic Data Initiative

Oncology Business Pushes Invitae’s Q2 Revenues up 18 Percent

10x Genomics Lowers Full-Year 2022 Revenue Guidance by Approximately $100M

Recent Tweets

LATEST ISSUE

ARCHIVE ISSUES

March 2022

September 2021

June 2021

March 2021

SUBSCRIBE